Search

Displaying results 2181 - 2190 of 2674 in total
  1. Target

    Ribosome-binding protein 1

    go.drugbank.com/bio_entities/BE0003466
    TargetHumans

    Acts as a ribosome receptor and mediates interaction between the ribosome and the endoplasmic reticulum membrane

    Synonyms: Ribosome receptor protein, 180 kDa ribosome receptor homolog
  2. Target

    Natural killer cells antigen CD94

    go.drugbank.com/bio_entities/BE0010559
    TargetHumans

    Immune receptor involved in self-nonself discrimination.

    Synonyms: NK cell receptor, Killer cell lectin-like receptor subfamily D member 1Function: HLA-A specific activating MHC class I receptor activity
  3. Target

    V-type immunoglobulin domain-containing suppressor of T-cell activation

    go.drugbank.com/bio_entities/BE0010797
    TargetHumans

    Immunoregulatory receptor which inhibits the T-cell response (PubMed:24691993). May promote differentiation of embryonic stem cells, by inhibiting BMP4 signaling (By similarity).

    Synonyms: Platelet receptor Gi24, V-set immunoregulatory receptor
  4. Drug

    Betula pendula tar oil

    go.drugbank.com/drugs/DB11361
    ApprovedNutraceutical

    [L1113] By the FDA, it is considered under the substances approved to be added to the food.

  5. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    FDA approved on June 15, 2011.

  6. Drug

    Technetium Tc-99m oxidronate

    go.drugbank.com/drugs/DB09139
    ApprovedWithdrawn

    [L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981.

  7. Drug

    Omega-3-carboxylic acids

    go.drugbank.com/drugs/DB09568
    ApprovedWithdrawn

    [A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386]

  8. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering

  9. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    [L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).

  10. Drug

    Miconazole

    go.drugbank.com/drugs/DB01110
    ApprovedInvestigationalVet approved

    [A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.